Jazz Pharmaceuticals (JAZZ) Asset Writedowns and Impairment (2014 - 2023)

Jazz Pharmaceuticals' Asset Writedowns and Impairment history runs 6 years deep, the most recent figure standing at $61.0 million for Q4 2023.

• In Q4 2023, Asset Writedowns and Impairment rose 145.65% year-over-year to $61.0 million; the TTM figure through Dec 2023 stood at $61.0 million (changed N/A YoY), while the FY2023 annual figure was $61.0 million, changed N/A from the prior year.
• Asset Writedowns and Impairment for Q4 2023 stood at $61.0 million, up from -$133.6 million in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $136.1 million in Q1 2020, with the low at -$133.6 million in Q4 2022.
• The 3-year median for Asset Writedowns and Impairment is $97.3 million (2022), against an average of $49.3 million.
• Peak annual rise in Asset Writedowns and Impairment reached 145.65% in 2023, while the deepest fall reached 145.65% in 2023.
• Jazz Pharmaceuticals' Asset Writedowns and Impairment stood at $136.1 million in 2020, then tumbled by 198.17% to -$133.6 million in 2022, then surged by 145.65% to $61.0 million in 2023.
• Business Quant data shows JAZZ's Asset Writedowns and Impairment at $61.0 million in Q4 2023, -$133.6 million in Q4 2022, and $133.6 million in Q3 2022.